KRAS and colorectal carcinoma: Subsequent clinical trials are currently investigating adagrasib as monotherapy or in combination with other anticancer agents in patients with advanced or metastatic solid tumors, including NSCLC and CRC, with the KRAS p.G12C mutation (Table 1).